Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
ARQL's Cash to Debt is ranked higher than
97% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 42.60 vs. ARQL: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ARQL' s Cash to Debt Range Over the Past 10 Years
Min: 0.92  Med: 25.92 Max: No Debt
Current: No Debt
Equity to Asset 0.81
ARQL's Equity to Asset is ranked higher than
67% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ARQL: 0.81 )
Ranked among companies with meaningful Equity to Asset only.
ARQL' s Equity to Asset Range Over the Past 10 Years
Min: -0.16  Med: 0.67 Max: 0.93
Current: 0.81
-0.16
0.93
Interest Coverage No Debt
ARQL's Interest Coverage is ranked higher than
97% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ARQL: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ARQL' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 3
Z-Score: -8.42
M-Score: -2.03
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -198.80
ARQL's Operating margin (%) is ranked lower than
59% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. ARQL: -198.80 )
Ranked among companies with meaningful Operating margin (%) only.
ARQL' s Operating margin (%) Range Over the Past 10 Years
Min: -790.25  Med: -153.58 Max: -23.41
Current: -198.8
-790.25
-23.41
Net-margin (%) -197.28
ARQL's Net-margin (%) is ranked lower than
59% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -81.84 vs. ARQL: -197.28 )
Ranked among companies with meaningful Net-margin (%) only.
ARQL' s Net-margin (%) Range Over the Past 10 Years
Min: -582.35  Med: -149 Max: -22.75
Current: -197.28
-582.35
-22.75
ROE (%) -45.10
ARQL's ROE (%) is ranked lower than
58% of the 858 Companies
in the Global Biotechnology industry.

( Industry Median: -31.92 vs. ARQL: -45.10 )
Ranked among companies with meaningful ROE (%) only.
ARQL' s ROE (%) Range Over the Past 10 Years
Min: -141.91  Med: -46.24 Max: -19.63
Current: -45.1
-141.91
-19.63
ROA (%) -33.72
ARQL's ROA (%) is ranked lower than
55% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. ARQL: -33.72 )
Ranked among companies with meaningful ROA (%) only.
ARQL' s ROA (%) Range Over the Past 10 Years
Min: -43.21  Med: -23.58 Max: -8.65
Current: -33.72
-43.21
-8.65
ROC (Joel Greenblatt) (%) -5820.77
ARQL's ROC (Joel Greenblatt) (%) is ranked lower than
81% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -387.57 vs. ARQL: -5820.77 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ARQL' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -7093.73  Med: -945.15 Max: -332.62
Current: -5820.77
-7093.73
-332.62
Revenue Growth (3Y)(%) -33.50
ARQL's Revenue Growth (3Y)(%) is ranked lower than
80% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 3.70 vs. ARQL: -33.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ARQL' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -61  Med: 9.6 Max: 45.3
Current: -33.5
-61
45.3
EBITDA Growth (3Y)(%) 10.80
ARQL's EBITDA Growth (3Y)(%) is ranked higher than
63% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. ARQL: 10.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ARQL' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -45.4  Med: 14.2 Max: 137.1
Current: 10.8
-45.4
137.1
EPS Growth (3Y)(%) 6.50
ARQL's EPS Growth (3Y)(%) is ranked higher than
64% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. ARQL: 6.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ARQL' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -44  Med: 2.1 Max: 132.1
Current: 6.5
-44
132.1
» ARQL's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-04)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

ARQL Guru Trades in Q3 2015

First Eagle Investment 8,719,968 sh (unchged)
Jim Simons 1,936,544 sh (-7.94%)
» More
Q4 2015

ARQL Guru Trades in Q4 2015

Jim Simons 2,270,089 sh (+17.22%)
First Eagle Investment 8,719,968 sh (unchged)
» More
Q1 2016

ARQL Guru Trades in Q1 2016

First Eagle Investment 10,825,233 sh (+24.14%)
First Eagle Investment 935,673 sh (unchged)
Jim Simons 2,147,660 sh (-5.39%)
» More
Q2 2016

ARQL Guru Trades in Q2 2016

First Eagle Investment 10,837,733 sh (+0.12%)
First Eagle Investment 935,673 sh (unchged)
Jim Simons 2,028,583 sh (-5.54%)
» More
» Details

Insider Trades

Latest Guru Trades with ARQL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:AMEX:OCX, NAS:SBBP, OTCPK:SLNCF, NAS:MRTX, NAS:ORMP, NAS:TRIL, NAS:AKAO, NAS:NVLS, NAS:AVXL, NAS:CTIC, NAS:SBPH, NAS:CRME, NAS:VVUS, NAS:KURA, NAS:CFRX, NAS:EBIO, NAS:PTIE, NAS:AKTX, OTCPK:DFFND, OTCPK:RCAR » details
Traded in other countries:AQL.Germany,
Arqule Inc is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics.

Arqule Inc was organized as a Delaware corporation in 1993 in Delaware. The Company is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. It employ technologies such as its ArQule Kinase Inhibitor Platform ("AKIPTM") to design and develop drugs that have the potential to fulfill this mission. Its product candidates and programs span a continuum of research and development ranging from drug discovery to advanced clinical testing. Its product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase. C-Met is a promising target for cancer therapy, based on its multiple roles in cancerous cell proliferation, tumor spread, new blood vessel formation and resistance to certain drug therapies. The Company and its partners, Daiichi Sankyo Co., Ltd. ('Daiichi Sankyo') and Kyowa Hakko Kirin Co., Ltd. ('Kyowa Hakko Kirin'), are implementing a clinical development program designed to realize the broad potential of tivantinib as a well-tolerated single agent and in combination with other anti-cancer therapies in a number of disease indications The Company has licensed commercial rights to tivantinib for human cancer indications to Daiichi Sankyo in the U.S., Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin. Its proprietary pipeline is directed toward molecular targets and biological processes with demonstrated roles in the development of human cancers. The advanced candidates in this pipeline are ARQ 087, an inhibitor of fibroblast growth factor receptor, ARQ 621, an inhibitor of the Eg5 kinesin motor protein, and ARQ 736, an inhibitor of the RAF kinases, all of which are in Phase 1 clinical testing. Its drug discovery efforts are engaged mainly on AKIP, which it is using to generate compounds designed to inhibit kinases without competing with adenosine triphosphate ('ATP') for binding to the target kinase, as well as other types of kinase inhibitors. ATP is a chemical found in all living cells and is the energy source involved in a variety of physiological processes. The Company faces competition from pharmaceutical companies, biotechnology companies and academic and research organizations. The Company's product candidates, as well as the activities associated with their research, development and commercialization, are subject to extensive regulation by the FDA in the United States and by comparable authorities in other countries.

Ratios

vs
industry
vs
history
P/B 2.91
ARQL's P/B is ranked higher than
60% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: 3.67 vs. ARQL: 2.91 )
Ranked among companies with meaningful P/B only.
ARQL' s P/B Range Over the Past 10 Years
Min: 1.46  Med: 3.04 Max: 113.05
Current: 2.91
1.46
113.05
P/S 11.99
ARQL's P/S is ranked lower than
52% of the 681 Companies
in the Global Biotechnology industry.

( Industry Median: 11.30 vs. ARQL: 11.99 )
Ranked among companies with meaningful P/S only.
ARQL' s P/S Range Over the Past 10 Years
Min: 2.78  Med: 9.37 Max: 51.45
Current: 11.99
2.78
51.45
Current Ratio 5.10
ARQL's Current Ratio is ranked higher than
54% of the 918 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. ARQL: 5.10 )
Ranked among companies with meaningful Current Ratio only.
ARQL' s Current Ratio Range Over the Past 10 Years
Min: 1.06  Med: 3.37 Max: 12.74
Current: 5.1
1.06
12.74
Quick Ratio 5.10
ARQL's Quick Ratio is ranked higher than
55% of the 918 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. ARQL: 5.10 )
Ranked among companies with meaningful Quick Ratio only.
ARQL' s Quick Ratio Range Over the Past 10 Years
Min: 1.06  Med: 3.36 Max: 12.74
Current: 5.1
1.06
12.74

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.30
ARQL's 3-Year Average Share Buyback Ratio is ranked higher than
93% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: -11.50 vs. ARQL: -0.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ARQL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -18.9  Med: -11.7 Max: -0.3
Current: -0.3
-18.9
-0.3

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.96
ARQL's Price/Net Cash is ranked higher than
76% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 5.78 vs. ARQL: 2.96 )
Ranked among companies with meaningful Price/Net Cash only.
ARQL' s Price/Net Cash Range Over the Past 10 Years
Min: 1.47  Med: 4 Max: 646
Current: 2.96
1.47
646
Price/Net Current Asset Value 2.96
ARQL's Price/Net Current Asset Value is ranked higher than
75% of the 618 Companies
in the Global Biotechnology industry.

( Industry Median: 5.45 vs. ARQL: 2.96 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ARQL' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.29  Med: 3.76 Max: 252.5
Current: 2.96
1.29
252.5
Price/Tangible Book 2.90
ARQL's Price/Tangible Book is ranked higher than
67% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: 4.38 vs. ARQL: 2.90 )
Ranked among companies with meaningful Price/Tangible Book only.
ARQL' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.57  Med: 2.63 Max: 96.95
Current: 2.9
0.57
96.95
Price/Median PS Value 1.28
ARQL's Price/Median PS Value is ranked lower than
66% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. ARQL: 1.28 )
Ranked among companies with meaningful Price/Median PS Value only.
ARQL' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.09  Med: 0.85 Max: 8.31
Current: 1.28
0.09
8.31
Earnings Yield (Greenblatt) (%) -26.20
ARQL's Earnings Yield (Greenblatt) (%) is ranked lower than
74% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -8.90 vs. ARQL: -26.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ARQL' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -230.1  Med: 0 Max: 0
Current: -26.2
-230.1
0

More Statistics

Revenue (TTM) (Mil) $7.75
EPS (TTM) $ -0.24
Beta1.13
Short Percentage of Float0.22%
52-Week Range $1.37 - 2.65
Shares Outstanding (Mil)71.11

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 14 29
EPS ($) -0.27 -0.40
EPS w/o NRI ($) -0.27 -0.40
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for ARQL

Headlines

Articles On GuruFocus.com
Jean-Marie Eveillard Increases Stakes in Cancer Therapeutics Company Arqule Inc May 05 2015 
Jean-Marie Eveillard Adds to Stake in Arqule Inc. May 03 2015 
ArQule Inc. Reports Operating Results (10-Q) Nov 09 2010 
ArQule Inc. Reports Operating Results (10-Q) Aug 04 2010 
ArQule Inc. Reports Operating Results (10-Q) May 06 2010 
ArQule Inc. (ARQL) CEO Paolo Pucci buys 5,000 Shares Nov 13 2009 
ArQule Inc. Reports Operating Results (10-Q) Aug 07 2009 
ArQule Inc. (ARQL) CEO Paolo Pucci buys 2,500 Shares May 15 2009 
ArQule Inc. Reports Operating Results (10-Q) May 08 2009 

More From Other Websites
ETF’s with exposure to ArQule, Inc. : August 25, 2016 Aug 25 2016
ETF’s with exposure to ArQule, Inc. : August 11, 2016 Aug 11 2016
ARQULE INC Financials Aug 06 2016
ArQule, Inc. :ARQL-US: Earnings Analysis: Q2, 2016 By the Numbers : August 5, 2016 Aug 05 2016
Edited Transcript of ARQL earnings conference call or presentation 3-Aug-16 1:00pm GMT Aug 03 2016
ARQULE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 03 2016
ArQule To Report Second Quarter 2016 Financial Results On August 3, 2016 Aug 03 2016
ArQule reports 2Q loss Aug 03 2016
ArQule reports 2Q loss Aug 03 2016
Q2 2016 ArQule Inc Earnings Release - Before Market Open Aug 03 2016
ArQule Reports Second Quarter 2016 Financial Results Aug 03 2016
ArQule To Report Second Quarter 2016 Financial Results On August 3, 2016 Jul 20 2016
ArQule Presents Preclinical Data for ARQ 531, a Proprietary Reversible Inhibitor of Wild Type and... Jul 18 2016
ArQule to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference on July 12, 2016 Jul 05 2016
Here’s What The ArQule, Inc. (ARQL) Data Really Means Jul 01 2016
ArQule Presents Preliminary Clinical Data for ARQ 087 Demonstrating Evidence of Anticancer Activity... Jun 30 2016
Forget Valeant, Invest in These Attractive Drug Stocks Instead Jun 28 2016
ArQule (ARQL) Shows Strength: Stock Adds 8% in Session Jun 23 2016
ArQule to Present Preliminary Phase 1/2 Data for FGFR Inhibitor, ARQ 087, in Intrahepatic... Jun 23 2016
ETF’s with exposure to ArQule, Inc. : June 20, 2016 Jun 20 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)